Get started
Work

Abstract P5-13-04: A phase II neoadjuvant trial of MK-2206, an AKT inhibitor, in combination with anastrozole for clinical stage 2 or 3 PIK3CA mutant estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)

Year: 2016
Type: conference-abstract
DOI: 10.1158/1538-7445.sabcs15-p5-13-04
Authors: CX Ma, VJ Suman, M Goetz, D Northfelt, M Burkard, F Ademuyiwa, M Naughton, J Margenthaler, R Aft, R Gray, A Tavaarwerk, L Wilke, T Haddad, T Moynihan, C Loprinzi, T Hieken, J Hoog, Z Guo, J Han, K Vij, E Mardis, S Sanati, H Al-Kateb, L Doyle, C Erlichman, MJ Ellis
Institutions: National Institutes of Health, University of Wisconsin System, Mayo Clinic, University of Wisconsin–Madison, Baylor College of Medicine, Mayo Clinic in Arizona, National Cancer Institute
Language: English
Subfield: Cancer Research
Open Access status: closed
OpenAlex ID: W2402069588
Cites:
Cited by: 3
Related to: 10